(Source: The Hindu Business Line, 08 April 2011)
The Zydus Cadila Chairman and Managing Director, Mr Pankaj R. Patel, said: “We have been building a promising pipeline of new molecular entities at the Zydus Research Centre.”
ZYGK1 is a new molecular entity (NME), which is a ‘potent and orally administered small molecule glucokinase activator’. In multiple pre-clinical models of Type 2 diabetes, ZYGK1 was found to be effective in controlling both fasting and non-fasting blood glucose, the company added. A NME is a molecule developed by the innovator company in the early drug discovery stage, which after undergoing clinical trials could translate into a drug. Read more
0 comments:
Post a Comment